Precision BioSciences, Inc.
NASDAQ Global SelectTotal Valuation
Precision BioSciences, Inc. carries a market capitalization of 77.48M, placing it among publicly traded companies globally. Its enterprise value stands at -3.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 77.48M |
| Enterprise Value | -3.37M |
Share Statistics
Precision BioSciences, Inc. currently has 25.81M shares outstanding.
| Shares Outstanding | 25.81M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.03, and the price-to-book ratio stands at -0.17.
| PE Ratio | N/A |
| PS Ratio | 2.03 |
| PB Ratio | -0.17 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | -1.57 |
| P/OCF Ratio | -1.56 |
Enterprise Valuation
| EV / Sales | 82.59 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Precision BioSciences, Inc. maintains a current ratio of 14.02, meaning it holds 14.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.90, indicating elevated leverage, while an interest coverage ratio of -26.41 demonstrates limited ability to service its debt obligations.
| Current Ratio | 14.02 |
| Quick Ratio | 12.81 |
| Debt / Equity | 5.90 |
| Debt / EBITDA | -0.12 |
| Interest Coverage | -26.41 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -32.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 9.05 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Precision BioSciences, Inc.'s stock has gained approximately 18.43137% over the past 52 weeks. The 50-day moving average sits at 7.03, while the 200-day moving average is 5.55.
| Beta (5Y) | N/A |
| 52-Week Price Change | 18.43137% |
| 50-Day Moving Average | 7.03 |
| 200-Day Moving Average | 5.55 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Precision BioSciences, Inc. generated 45.07M in revenue and converted that into -43.60M in net income, yielding earnings per share of -2.67. EBITDA reached -36.42M, while operating income came in at -39.11M.
| Revenue | 45.07M |
| Gross Profit | N/A |
| Operating Income | -39.11M |
| Pretax Income | -44.48M |
| Net Income | -43.60M |
| EBITDA | -36.42M |
| EBIT | -39.11M |
| Earnings Per Share (EPS) | -2.67 |
Balance Sheet
Precision BioSciences, Inc. holds 99.37M in cash and equivalents against 4.49M in total debt, resulting in a net debt position of -99.37M. Total book value stands at -546.63M, with working capital of 100.94M providing operational flexibility.
| Cash & Cash Equivalents | 99.37M |
| Total Debt | 4.49M |
| Net Debt | -99.37M |
| Equity (Book Value) | -546.63M |
| Book Value Per Share | -32.86 |
| Working Capital | 100.94M |
Cash Flow
Precision BioSciences, Inc. produced -58.73M in operating cash flow over the past twelve months. After subtracting -504,000.00 in capital expenditures, free cash flow totaled -59.23M - equivalent to -3.56 per share.
| Operating Cash Flow | -58.73M |
| Capital Expenditures | -504,000.00 |
| Free Cash Flow | -59.23M |
| FCF Per Share | -3.56 |
Margins
Precision BioSciences, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -86.77 and net profit margin of -96.73 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -86.77 |
| Pretax Margin | -98.70 |
| Profit Margin | -96.73 |
| EBITDA Margin | -80.81 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -93.13 |
| FCF Yield | -63.51 |
Stock Splits
Precision BioSciences, Inc.'s most recent stock split took place on February 14, 2024 with a 30:1 split ratio.
| Last Split Date | 2/14/2024 |
| Split Ratio | 30:1 |
Scores
Precision BioSciences, Inc. posts an Altman Z-Score of -4.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.29 |